Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy
Jens O. Brömme(University of Bern), Daniel M. Aebersold(University of Bern), Pirus Ghadjar(Humboldt-Universität zu Berlin), Ludwig Plaßwilm(University of St. Gallen), A. Arnold(University of Bern), Andreas Geretschläger(University of Bern), M. Schmücking(University of Bern), Dominic Leiser(Paul Scherrer Institute), Roland Giger(University of Bern), Daniel Rauch(Washington University in St. Louis)
Cited by 11
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
|Annals of Oncology|2016|140